NeoGenomics’ Solid Tumor Test Gets New York State Approval
NeoGenomics received conditional approval from the New York State Department of Health for its Neo Comprehensive Solid Tumor and NeoTYPE DNA & RNA Lung assays.
Read MorePosted by Andy Lundin | Oct 22, 2024 | Lung Cancer, Molecular Diagnostics |
NeoGenomics received conditional approval from the New York State Department of Health for its Neo Comprehensive Solid Tumor and NeoTYPE DNA & RNA Lung assays.
Read MorePosted by Andy Lundin | Oct 21, 2024 | Unknown Origin & Other Cancer Types |
Thermo Fisher’s CDx for identifying glioma patients eligible for treatment with Servier Pharmaceuticals’ VORANIGO gets FDA approval.
Read MorePosted by Andy Lundin | Sep 30, 2024 | Molecular Diagnostic Analyzers |
The digital PCR system brings precise DNA and RNA quantification to diagnostics for applications like cancer monitoring and liquid biopsies.
Read MorePosted by Andy Lundin | Sep 17, 2024 | Digital Pathology |
Roche’s navify digital pathology enterprise software now integrates a range of AI-driven algorithms, enabling enhanced cancer diagnostics.
Read MorePosted by Andy Lundin | Sep 13, 2024 | Cardiovascular |
A new review finds that 20% of the global population carries a genetic risk for cardiovascular diseases due to high levels of lipoprotein(a).
Read More